Shire says that by moving to a world-class IS service partner it expects to improve the cost-effectiveness, efficiency and scalability of its IS Operations to support the continuation of its strong record of expansion, acquisition and new product innovation.
John Cogan, Vice-President, IS Operations at Shire, said: ‘Working with Capgemini will strengthen our ability to increase the scope and scale of our activities, and do so with the agility and cost-effectiveness that the fast-moving world of specialty biopharmaceuticals requires.’
Shire says that key factors in its decision to appoint Capgemini included proven ability to support multinational companies in high-technology businesses especially pharmaceuticals, its collaborative and practical approach, and its Rightshore® strategy using Capgemini centres around the world to give Shire users the right balance of service, quality and cost.
Jerry Clark, Business Development Director at Capgemini, said: ‘We are naturally delighted to have succeeded in winning this important global contract and we look forward to working with Shire to deliver the quality of service and benefits that Shire requires.’
Capgemini will take over responsibilities in December 2007 in the key areas of IS infrastructure support, IS and data centre operations, and user support, with a new multi-lingual service desk to support more than 3,000 Shire users worldwide.
Jon Scott, Senior Vice President, Shared Business Services for Shire said: ‘It was evident during the bid process that Shire and Capgemini are a great cultural fit. We share the same commitment to dynamism and efficiency, and the same can-do outlook. We look forward to a long and healthy relationship.’
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
Capgemini, one of the world’s foremost providers of Consulting, Technology and Outsourcing services, enables its clients to transform and perform through technologies. Capgemini provides its clients with insights and capabilities that boost their freedom to achieve superior results through a unique way of working, which it calls the Collaborative Business Experience. Capgemini reported 2006 global revenues of EUR 7.7 billion and employs more than 80,000 people worldwide.
More information is available at www.capgemini.com.